These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Successful treatment of metastatic mucosal melanoma with a Del579 c-KIT mutation by imatinib after treatment of anti-PD-1 antibody. Yamashita C; Otsuka A; Nomura M; Honda T; Kabashima K J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):e92-e93. PubMed ID: 30199578 [No Abstract] [Full Text] [Related]
3. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439 [TBL] [Abstract][Full Text] [Related]
4. Tumour heterogeneity of mucosal melanomas during treatment with imatinib. Schoenewolf NL; Urosevic-Maiwald M; Dummer R Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997 [TBL] [Abstract][Full Text] [Related]
5. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579 [TBL] [Abstract][Full Text] [Related]
6. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Rapisuwon S; Parks K; Al-Refaie W; Atkins MB Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536 [TBL] [Abstract][Full Text] [Related]
7. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report. Prosvicova J; Lukesova S; Kopecky J; Grim J; Papik Z; Kolarova R; Navratilova B; Dubreuil P; Agopian J; Mansfield C; Moussy A; Hermine O Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):695-7. PubMed ID: 26725706 [TBL] [Abstract][Full Text] [Related]
8. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. Meng D; Carvajal RD Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374 [TBL] [Abstract][Full Text] [Related]
10. Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493 [TBL] [Abstract][Full Text] [Related]
11. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy. Consoli F; Manganoni AM; Grisanti S; Petrelli F; Venturini M; Rangoni G; Guarneri F; Incardona P; Vermi W; Calzavara Pinton PG; Berruti A PLoS One; 2019; 14(4):e0214884. PubMed ID: 30939167 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic implications of KIT in melanoma. Postow MA; Carvajal RD Cancer J; 2012; 18(2):137-41. PubMed ID: 22453014 [TBL] [Abstract][Full Text] [Related]
13. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Papaspyrou G; Garbe C; Schadendorf D; Werner JA; Hauschild A; Egberts F Melanoma Res; 2011 Dec; 21(6):475-82. PubMed ID: 21897303 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report. Edmondson LA; Smith LV; Mallik A J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337 [TBL] [Abstract][Full Text] [Related]
17. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468 [TBL] [Abstract][Full Text] [Related]
18. Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma. Fukuchi K; Hikawa M; Sano Y; Kasuya A; Aoshima M; Tatsuno K; Nakamura Y; Kosugi I; Tokura Y J Dermatol; 2019 Oct; 46(10):e359-e360. PubMed ID: 30985014 [No Abstract] [Full Text] [Related]
19. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901 [TBL] [Abstract][Full Text] [Related]
20. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor. Itoh M; Goto A; Wakasugi H; Yoshida Y; Matsunaga Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Arimura Y; Shinomura Y Int J Clin Oncol; 2011 Aug; 16(4):428-34. PubMed ID: 21069551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]